Showing results (411-420 of 537) with videos related to
Sort By:
Pageof 54
Cell Host & Microbe|March 11, 2016
A Cytomegalovirus Peptide-Specific Antibody Alters Natural Killer Cell Homeostasis and Is Shared in Several Autoimmune DiseasesYu Liu, Rong Mu, Ya-Ping Gao, et al.Nature Medicine|October 6, 2025
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialIain B McInnes, Laura C Coates, Philip J Mease, et al.The Journal of Rheumatology|March 9, 2007
Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centersBarry Bresnihan, Danielle M Gerlag, Terence Rooney, et al.Rheumatology and Therapy|August 31, 2024
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.Rheumatology and Therapy|May 10, 2025
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2009
IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammationMariola Kurowska-Stolarska, Bartosz Stolarski, Peter Kewin, et al.Advances in Therapy|August 10, 2022
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.Angiogenesis|January 13, 2018
IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cellsHatem A Elshabrawy, Michael V Volin, Abdul B Essani, et al.Annals of the Rheumatic Diseases|February 11, 2025
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.Pageof 54